PDB21 HEALTH CARE RESOURCE UTILIZATION AND COST IN TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND ROSIGLITAZONE (RSG)- THE RESULT TRIAL
Abstract
Authors
WH Herman R Horblyuk B Arondekar MC ONeill B Kravitz MA Heise MI Freed